Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

Clicks: 265
ID: 268897
2018
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
This study assessed the efficacy and safety of ribavirin-free coformulated glecaprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or compensated cirrhosis, a patient population with limited treatment options. SURVEYOR-II, Part 3 was ā€¦
Reference Key
d2018hepatologyglecaprevir/pibrentasvir Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Wyles D;Poordad F;Wang S;Alric L;Felizarta F;Kwo PY;Maliakkal B;Agarwal K;Hassanein T;Weilert F;Lee SS;Kort J;Lovell SS;Liu R;Lin CW;Pilot-Matias T;Krishnan P;Mensa FJ;;
Journal Hepatology (Baltimore, Md.)
Year 2018
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/28926120
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine adult female male aged middle aged Clinical Trial Phase III Randomized Controlled Trial Multicenter Study Genotype chronic / blood drug therapy combination chronic / complications chronic / virology chronic / drug therapy* alanine transaminase / blood antiviral agents / administration & dosage* fred poordad sustained virologic response Quinoxalines / adverse effects benzimidazoles / administration & dosage* federico j mensa benzimidazoles / adverse effects quinoxalines / administration & dosage* sulfonamides / administration & dosage* sulfonamides / adverse effects pmid:28926120 pmc5817409 doi:10.1002/hep.29541 david wyles liver cirrhosis / etiology*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.